Drug intelligence / Profile preview

dapsone + flutamide + tea tree oil

Development stage: Phase 2
Lead developer: Mansoura University
Modality: Small Molecules
Administration: Topical

Overview

DAP-FLU ME is an investigational topical combination micro-emulsion (o/w type) formulation developed by researchers at Mansoura University for the treatment of mild to moderate acne vulgaris. It contains 5% dapsone, 2.5% flutamide, and 5% tea tree oil. Dapsone provides antibacterial and anti-inflammatory effects, while flutamide acts as a non-steroidal anti-androgen to target sebaceous gland overactivity. Tea tree oil serves as both an antibacterial agent and a component of the micro-emulsion base. This topical approach aims to deliver therapeutic efficacy while minimizing the systemic side effects associated with oral administration of dapsone or flutamide.

Other names: DAP/FLU Micro-emulsion

Targets

AR (Adrenergic receptors)DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on dapsone + flutamide + tea tree oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dapsone + flutamide + tea tree oil.